Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Neighbors Help Cancer Cells Resist Treatment

Published: Wednesday, July 25, 2012
Last Updated: Wednesday, July 25, 2012
Bookmark and Share
New study reveals that surrounding cells help tumors develop resistance to drugs.

A new study shows that surrounding cells can help tumors develop resistance to drugs. The finding may change the way researchers approach the treatment of many cancers.

Drugs designed to target unique tumor proteins hold great promise for cancer treatment. However, many tumors become resistant to treatment over time.

For example, deadly skin cancers called melanomas often harbor a mutant form of a gene known as BRAF.

Although these particular tumors initially respond well to a class of drugs called RAF inhibitors, in many cases the treatment is only partly successful, and the tumors later recur within 6 months.

A research team led by Dr. Todd Golub at the Broad Institute and the Dana-Farber Cancer Institute set out to explore factors in the tumor's environment that might play a role in drug resistance.

They developed a co-culture system in which tumor cells are grown in the laboratory along with stromal cells-cells from the tissue that surrounds tumors. They then tested the ability of the stromal cells to affect drug sensitivity.

The researchers cultured 45 human cancer cell lines either alone or in combination with a panel of about 2 dozen human stromal cell lines. They then tested increasing doses of 35 widely used anticancer drugs, including 23 targeted drugs.

Their work was funded partly by NIH's National Cancer Institute (NCI). Results appeared in the early online edition of Nature on July 4, 2012.

The scientists found that anticancer drugs were often less effective when the tumor cells were cultured along with stromal cells. Significantly, stromal cells led to increased resistance to 15 of the 23 targeted drugs (65%).

The team next explored how stromal cells affected tumor resistance to a RAF inhibitor called PLX4720. A similar compound, vemurafenib, was recently approved by the FDA for treating BRAF-mutant melanoma.

By testing the growth media of the stromal cells, the scientists discovered that the cells released a compound called hepatocyte growth factor (HGF), which helped the tumor cells become resistant.

Further experiments revealed the pathway that allowed the tumor cells to resist the RAF inhibitor. Among their findings was that HGF activated a tumor cell receptor called MET.

The researchers asked whether HGF plays a role in patients with BRAF-mutant melanoma. They examined biopsy samples obtained immediately before treatment and found HGF in stromal cells from 23 of 34 patients (68%).

They also found that patients whose stromal cells secreted HGF had a significantly poorer response to treatment.

The scientists uncovered a similar resistance mechanism in BRAF-mutant colorectal and glioblastoma cell lines.

They also discovered that they could reverse drug resistance in the BRAF-mutant melanoma cell lines by inhibiting RAF plus either HGF or MET.

This finding suggests a potential therapeutic strategy. The researchers note that several inhibitors of HGF or MET are currently in clinical development.

“Historically, researchers would go to great lengths to pluck out tumor cells from a sample and discard the rest of the tissue,” Golub says. “But what we're finding now is that those non-tumor cells that make up the microenvironment may be an important source of drug resistance.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Thursday, July 02, 2015
Drugs that Activate Brain Stem Cells May Reverse Multiple Sclerosis
NIH-funded study identifies over-the-counter compounds that may replace damaged cells.
Tuesday, April 21, 2015
Allergy Drug Inhibits Hepatitis C in Mice
NIH study suggests alternative drug to treat virus.
Friday, April 10, 2015
Barrier-Breaking Drug May Lead to Spinal Cord Injury Treatments
NIH-funded scientists take first step towards developing promising new drug.
Thursday, December 04, 2014
Two Drugs are No More Effective Than One to Treat Common Kidney Disease
NIH study finds limited kidney benefit from more rigorous blood pressure treatment.
Saturday, November 29, 2014
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Monday, November 10, 2014
First Drug Candidate from NIH Program Acquired by Baxter
Potential treatment targets sickle cell disease.
Tuesday, July 15, 2014
Drug Does Not Improve Set of Cardiovascular Outcomes for Diastolic Heart Failure
NIH-supported study finds drug does appear to reduce hospitalizations for diastolic heart failure.
Tuesday, April 15, 2014
NIH, Industry and Non-Profits Join Forces to Speed Validation of Disease Targets
Goal is to develop new treatments earlier, beginning with Alzheimer's, type 2 diabetes, and autoimmune disorders.
Tuesday, February 11, 2014
Tobacco, Drug Use in Pregnancy Can Double Risk of Stillbirth
NIH network study documents elevated risk associated with marijuana, other substances.
Tuesday, December 24, 2013
Exploring Structure-Activity Data Using the Landscape Paradigm
Structure-activity relationships represent a core aspect of medicinal chemistry.
Friday, November 08, 2013
NIH Launches Trial for Rare Degenerative Muscle Disease Treatment
Clinical trial to evaluate the drug candidate DEX-M74 as a treatment for HIBM.
Tuesday, September 25, 2012
NIH Researchers Implicate Unique Cell Type in Multiple Sclerosis
Study reveals new effects of the investigational MS drug daclizumab.
Friday, August 03, 2012
NIH Funds Development of Tissue Chips to Help Predict Drug Safety
DARPA and FDA to collaborate on therapeutic development initiative.
Wednesday, July 25, 2012
NIH to Test Maraviroc-Based Drug Regimens for HIV Prevention
Safety, tolerability study to enroll MSM in the United States and Puerto Rico.
Thursday, July 19, 2012
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!